AKT1, AKT serine/threonine kinase 1, 207

N. diseases: 1250; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE This is the first evidence that Tan-Ⅰ induced apoptosis and promoted autophagy via the inactivation of PI3K/AKT/mTOR pathway on ovarian cancer and further inhibited tumour growth, which might be considered as effective strategy. 31820522 2020
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer. 31639424 2020
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 AlteredExpression disease BEFREE The addition of VEGF, IGF-1, and IL-8 weakened the inhibitory effect of DIRAS3 on ERK/AKT activity and reduced DIRAS3-mediated TFEB or FOXo3a nuclear localization and MAPLC3B expression in ovarian cancer cells. 30620384 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. 31284467 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Taken all data together, these findings demonstrated that the absence of SMURF1 repressed cell proliferation, invasive capability, and EMT process in ovarian cancer through DAB2IP/AKT/Skp2 signaling loops, suggesting that SMURF1 may serve as a new potential therapeutic agent for ovarian cancer. 30672020 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE The newly identified miR-99a/HOXA1/AKT/mTOR axis provides novel insight into the pathogenesis of ovarian cancer. 31210292 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC. 31128298 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE The PI3K/AKT/mTOR signaling pathway is considered as a promising therapeutic target in the treatment of ovarian cancer (OC); however, inhibition of this pathway only exhibited moderate clinical efficacy when tested clinically. 30972187 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Evaluation of ovarian cancer risk in granulosa cells treated with steroid-depleted endometriosis serum: Role of NF-κB/RelA and AKT. 30515820 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit cisplatin-induced apoptosis and autophagy in ovarian cancer cells resulting in cisplatin resistance. 30129654 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Likewise, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is also a central regulator of the ovarian cancer. 29401696 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 AlteredExpression disease BEFREE SNHG16 may activate phosphorylation of AKT and upregulate the expression of MMP9 to promote cell proliferation, invasion and migration of ovarian cancer. 29461589 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE These data suggested that PI3K induced epithelial-to-mesenchymal transition and promoted cell migration and invasion by activating the PI3K/AKT pathway in ovarian cancer. 30245957 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Gene composition analyses of the disrupted modules revealed five common genes (mitogen‑activated protein kinase 1, phosphoinositide 3‑kinase‑encoding catalytic 110‑KDα, AKT serine/threonine kinase 1, cyclin D1 and tumor protein P53) across the four subtypes of ovarian cancer. 28983627 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Many studies involving patients with cisplatin-resistant ovarian cancer have shown that AKT activation leads to inhibition of apoptosis. 27935869 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. 25677064 2015
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Together, REDD1 and p-AKT over-expression may serve as a prognostic biomarker in OC, but KRAS mutations and REDD1 protein over-expression were not correlated in OC. 25337238 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Our results indicate that FAK inhibition can suppress ovarian cancer cells migration and invasion through inhibiting downstream signaling (PI3K/AKT), which might be a therapeutic target or biomarker for ovarian cancer. 24115647 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 AlteredExpression disease BEFREE Moreover, VEGF expression could reverse the effect of miR-718 on ovarian cancer by increasing the levels of phosphorylated AKT. 24815691 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. 25176450 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 AlteredExpression disease BEFREE Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. 23869765 2013
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE This review focuses on recent research on the PI3K/AKT/mTOR pathway and its role in the progression and tumorigensis of ovarian cancer. 23591839 2013
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease BEFREE Genomic complexity and AKT dependence in serous ovarian cancer. 22328975 2012
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 Biomarker disease CTD_human Importantly, we found that ΔNp63α, AKT1, and phospho-AKT levels are greater in 2008CI3 CDDP-resistant ovarian cancer cells than in 2008 CDDP-sensitive cells. siRNA-mediated knockdown of ΔNp63α expression dramatically decreased AKT1 expression, whereas knockdown of either ΔNp63α or AKT1 decreased cell proliferation and increased death of ovarian and head/neck cancer cells. 21266360 2011
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.700 AlteredExpression disease LHGDN Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. 19067848 2008